Hypertension during vascular endothelial growth factor inhibition: Focus on nitric oxide, endothelin-1, and oxidative stress

Antioxidants and Redox Signaling

Volumn 20, Issue 1, 2014, Pages 135-145

  Lankhorst, Stephanie ^a   Kappers, Mariëtte H W ^a   Van Esch, Joep H M ^a   Danser, A H Jan ^a   Van Den Meiracker, Anton H ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SUNITINIB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; BIOAVAILABILITY; HUMAN; HYPERTENSION; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ENDOTHELIN-1; HUMANS; HYPERTENSION; NITRIC OXIDE; OXIDATIVE STRESS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84891797083     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5244     Document Type: Review

References (94)

1. Ambs S, Merriam WG, Ogunfusika MO, Bennett WP, Ishibe N, Hussain SP, et al. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 4:1371-1376, 1998.
2. Bagnato A and Rosano L. The endothelin axis in cancer. Int J Biochem Cell Biol 40:1443-1451, 2008.
3. Banfor PN, Franklin PA, Segreti JA, Widomski DL, Davidsen SK, Albert DH, et al. ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats. J Cardiovasc Pharmacol 53:173-178, 2009.
4. Bono P, Elfving H, Utriainen T, Osterlund P, Saarto T, Alanko T, and Joensuu H. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 20:393-394, 2009.
5. Bouallegue A, Daou GB, and Srivastava AK. Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr Vasc Pharmacol 5:45-52, 2007.
6. Bouloumie A, Schini-Kerth VB, and Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 41:773-780, 1999.
7. Carmeliet P and Collen D. Genetic analysis of the plasminogen and coagulation system in mice. Haemostasis 26 Suppl 4:132-153, 1996.
8. Case J, Ingram DA, and Haneline LS. Oxidative stress impairs endothelial progenitor cell function. Antioxid Redox Signal 10:1895-1907, 2008.
9. Chowdhary S and Townend JN. Nitric oxide and hypertension: not just an endothelium derived relaxing factor! J Hum Hypertens 15:219-227, 2001.
10. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, and Johnson DH. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28:949-954, 2010.
11. Dong F, Zhang X, Wold LE, Ren Q, Zhang Z, and Ren J. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol 145:323-333, 2005.
12. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368-4380, 2002.
13. Ellis LM and Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579-591, 2008.
14. Escalante CP and Zalpour A. Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. Cardiol Res Pract 2011:816897, 2011.
15. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, and Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 140:947-959, 1998.
16. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, and Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 54:652-658, 2009.
17. Fernandez-Patron C, Radomski MW, and Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85:906-911, 1999.
18. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581-611, 2004.
19. Ferrara N and Kerbel RS. Angiogenesis as a therapeutic target. Nature 438:967-974, 2005.
20. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186, 1971.
21. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A 98:2604-2609, 2001.
22. Fukumura D, Kashiwagi S, and Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 6:521-534, 2006.
23. Gelinas DS, Bernatchez PN, Rollin S, Bazan NG, and Sirois MG. Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways. Br J Pharmacol 137:1021-1030, 2002.
24. Griendling KK, Sorescu D, and Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86:494-501, 2000.
25. Groenewegen G, Walraven M, Vermaat J, de Gast B, Witteveen E, Giles R, et al. Targeting the endothelin axis with atrasentan, in combination with IFN-Alpha, in metastatic renal cell carcinoma. Br J Cancer 106:284-289, 2012.
26. Gu JW, Manning RD, Jr., Young E, Shparago M, Sartin B, and Bailey AP. Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats. Am J Physiol Regul Integr Comp Physiol 297:R142-R148, 2009.
27. Gurevich F and Perazella MA. Renal effects of antiangiogenesis therapy: update for the internist. Am J Med 122:322-328, 2009.
28. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107:1359-1365, 2003.
29. Hood JD, Meininger CJ, Ziche M, and Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274: H1054-H1058, 1998.
30. Huang K, Andersson C, Roomans GM, Ito N, and Claesson-Welsh L. Signaling properties of VEGF receptor-1 and -2 homo-And heterodimers. Int J Biochem Cell Biol 33:315-324, 2001.
31. Humphreys BD and Atkins MB. Rapid development of hypertension by sorafenib: toxicity or target? Clin Cancer Res 15:5947-5949, 2009.
32. Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 4 Suppl 2:S62-S68, 2004.
33. Ivy SP, Wick JY, and Kaufman BM. An overview of smallmolecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6:569-579, 2009.
34. Iyer R, Fetterly G, Lugade A, and Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 11:1943-1955, 2010.
35. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327-338, 2009.
36. Kamba T and McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788-1795, 2007.
37. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:H560-H576, 2006.
38. Kandula P and Agarwal R. Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int 80:1271-1277, 2011.
39. Kappers MH, de Beer VJ, Zhou Z, Danser AHJ, Sleijfer S, Duncker DJ, et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 59:151-157, 2012.
40. Kappers MH, Smedts FM, Horn T, van Esch JHM, Sleijfer S, Leijten F, et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension 58:295-302, 2011.
41. Kappers MH, van Esch JHM, Sleijfer S, Danser AHJ, and van den Meiracker AH. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. J Hypertens 27:2297-2309, 2009.
42. Kappers MH, van Esch JHM, Sluiter W, Sleijfer S, Danser AHJ, and van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 56: 675-681, 2010.
43. Kappers MH, van Esch JHM, Smedts FM, de Krijger RR, Eechoute K, Mathijssen RH, et al. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab 96:3087-3094, 2011.
44. Kerbel RS. Tumor angiogenesis. N Engl J Med 358:2039-2049, 2008.
45. Khimji AK and Rockey DC. Endothelin-biology and disease. Cell Signal 22:1615-1625, 2010.
46. Kostourou V, Cartwright JE, Johnstone AP, Boult JK, Cullis ER, Whitley G, and Robinson SP. The role of tumourderived iNOS in tumour progression and angiogenesis. Br J Cancer 104:83-90, 2011.
47. Kroll J and Waltenberger J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 252:743-746, 1998.
48. Lavi S, Yang EH, Prasad A, Mathew V, Barsness GW, Rihal CS, et al. The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans. Hypertension 51:127-133, 2008.
49. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130:691-703, 2007.
50. Li B, Ogasawara AK, Yang R, Wei W, He GW, Zioncheck TF, et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 39:1095-1100, 2002.
51. Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ, and Chen AF. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in lowrenin hypertension. Circulation 107:1053-1058, 2003.
52. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102:596-604, 2010.
53. Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 15:6250-6257, 2009.
54. Maitland ML and Ratain MJ. Terminal ballistics of kinase inhibitors: there are no magic bullets. Ann Intern Med 145:702-703, 2006.
55. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 25:1751-1762, 2007.
56. Matsuura A, Kawashima S, Yamochi W, Hirata K, Yamaguchi T, Emoto N, and Yokoyama M. Vascular endothelial growth factor increases endothelin-converting enzyme expression in vascular endothelial cells. Biochem Biophys Res Commun 235:713-716, 1997.
57. Matsuura A, Yamochi W, Hirata K, Kawashima S, and Yokoyama M. Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension 32:89-95, 1998.
58. Mayer EL, Dallabrida SM, Rupnick MA, Redline WM, Hannagan K, Ismail NS, et al. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension 58:85-92, 2011.
59. Ng QS, Goh V, Milner J, Stratford MR, Folkes LK, Tozer GM, et al. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol 8:111-118, 2007.
60. Ohr M and Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother 13:585-591, 2012.
61. Okuda Y, Tsurumaru K, Suzuki S, Miyauchi T, Asano M, Hong Y, et al. Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells. Life Sci 63:477-484, 1998.
62. Pedram A, Razandi M, Hu RM, and Levin ER. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 272:17097-17103, 1997.
63. Pinto A, Merino M, Zamora P, Redondo A, Castelo B, and Espinosa E. Targeting the endothelin axis in prostate carcinoma. Tumour Biol 33:421-426, 2012.
64. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931-1939, 2011.
65. Rixe O, Billemont B, and Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol 18: 1117, 2007.
66. Roberts WG and Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 108:2369-2379, 1995.
67. Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, Karumanchi SA, and Humphreys BD. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 56:1131-1136, 2010.
68. Robinson ES, Khankin EV, Karumanchi SA, and Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 30:591-601, 2010.
69. Ruef J, Moser M, Kubler W, and Bode C. Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells. Cardiovasc Pathol 10:311-315, 2001.
70. Sandler A and Herbst R. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 12:4421s-4425s, 2006.
71. Sane DC, Anton L, and Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 7:193-201, 2004.
72. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, and Cascinu S. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20:227-230, 2009.
73. Schiffrin EL. Oxidative stress, nitric oxide synthase, and superoxide dismutase: a matter of imbalance underlies endothelial dysfunction in the human coronary circulation. Hypertension 51:31-32, 2008.
74. Schulz E, Jansen T, Wenzel P, Daiber A, and Munzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 10:1115-1126, 2008.
75. Sedeek MH, Llinas MT, Drummond H, Fortepiani L, Abram SR, Alexander BT, et al. Role of reactive oxygen species in endothelin-induced hypertension. Hypertension 42:806-810, 2003.
76. Seol HJ, Oh MJ, and Kim HJ. Endothelin-1 expression by vascular endothelial growth factor in human umbilical vein endothelial cells and aortic smooth muscle cells. Hypertens Pregnancy 30:295-301, 2011.
77. Shen BQ, Lee DY, and Zioncheck TF. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem 274:33057-33063, 1999.
78. Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, et al. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res 16:1834-1844, 2010.
79. Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens M, et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 14:3470-3476, 2008.
80. Stewart MW. Bevacizumab for retinopathy of prematurity. Ophthalmology 119:1091-1092; author reply 1092-1092.e1, 2012.
81. Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, and Lopez PF. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 32:434-457, 2012.
82. Syrigos KN, Karapanagiotou E, Boura P, Manegold C, and Harrington K. Bevacizumab-induced hypertension: pathogenesis and management. BioDrugs 25:159-169, 2011.
83. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull 34:1785-1788, 2011.
84. Tlemsani C, Mir O, Boudou-Rouquette P, Huillard O, Maley K, Ropert S, et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol 6:253-258, 2011.
85. Ushio-Fukai M and Alexander RW. Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol Cell Biochem 264:85-97, 2004.
86. Ushio-Fukai M and Urao N. Novel role of NADPH oxidase in angiogenesis and stem/progenitor cell function. Antioxid Redox Signal 11:2517-2533, 2009.
87. van Mourik JA, Romani de Wit T, and Voorberg J. Biogenesis and exocytosis of Weibel-Palade bodies. Histochem Cell Biol 117:113-122, 2002.
88. Verdonk K, Visser W, Russcher H, Danser AHJ, Steegers EA, and van den Meiracker AH. Differential diagnosis of preeclampsia: remember the soluble Fms-like tyrosine kinase 1/placental growth factor ratio. Hypertension 60:884-890, 2012.
89. Verheul HM and Pinedo HM. Inhibition of angiogenesis in cancer patients. Expert Opin Emerg Drugs 10:403-412, 2005.
90. Verheul HM and Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7:475-485, 2007.
91. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, and O?Dwyer PJ. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24:1363-1369, 2006.
92. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267:16066-16068, 1992.
93. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 31:1171-1177, 2003.
94. Zhu X, Wu S, Dahut WL, and Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-Analysis. Am J Kidney Dis 49:186-193, 2007.